Sam's Club Pharmacy vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Walmart-owned warehouse club pharmacy with 500+ locations; bulk purchasing enables discounted $4/$10 generics competing with Costco Pharmacy as part of Walmart's health services strategy.
About
Sam's Club Pharmacy is the pharmacy division operating within Sam's Club warehouse membership clubs, providing prescription filling, immunizations, health screenings, and specialty pharmacy services to Sam's Club members at competitive pricing leveraging Walmart's pharmaceutical purchasing scale. Part of Walmart Inc. (NYSE: WMT), Sam's Club Pharmacy operates more than 500 pharmacy locations inside Sam's Club warehouse clubs across the United States, offering members discounted prescription pricing as part of the Sam's Club membership value proposition.\n\nSam's Club Pharmacy's competitive advantage lies in Walmart's massive pharmaceutical purchasing power — the combined Walmart/Sam's Club pharmacy network is one of the largest in the US, enabling negotiated drug pricing that can undercut traditional retail pharmacies. Members access prescriptions at Sam's Club prices with convenient access during their warehouse shopping trips. The pharmacy offers $4/$10 generic prescription pricing for common medications, mail-order options, and immunization services.\n\nIn 2025, Sam's Club Pharmacy operates within Walmart's broader health strategy — Walmart Health (primary care clinics) and Walmart+ pharmacy benefits are being integrated to create a comprehensive health services ecosystem for Walmart and Sam's Club customers. The retail pharmacy market faces structural challenges from pharmacy benefit manager (PBM) reimbursement pressure that has forced independent and chain pharmacy closures. Sam's Club Pharmacy competes with Costco Pharmacy (similar warehouse model), CVS, Walgreens, and mail-order PBM pharmacies. The 2025 strategy focuses on expanding specialty pharmacy capabilities, integrating prescription benefits with Walmart+ membership, and growing immunization and preventive health services.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.